atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia
atai Life Sciences (ATAI) developed a new compound that could help treat cognitive impairment associated with schizophrenia (CIAS) such as attention deficits and issues with memory and executive function.
atai Life Sciences (ATAI) developed a new compound that could help treat cognitive impairment associated with schizophrenia.
The compound, RL-007, was tested on a cohort of 8 schizophrenic patients while continuing with their antipsychotic treatments. Using brain mapping and other biomarkers, researchers found that formulation improved cognition by activating receptors linked to learning and memory.
The findings were so promising that atai decided to spend additional resources to accelerate the compound into a Phase 2a trial, which should be completed by the end of the year.